U.S. doctors’ group endorses event-based PrEP


AMSTERDAM — For the first time, a U.S.-based doctors group has endorsed event-based PrEP use.

AIDSMap.com reported that the International Antiviral Society-USA (IAS-USA) made the recommendation during the International AIDS Conference in Amsterdam last month.

In this case, event-based means PrEP is given on demand instead of a regular daily dose. According to AIDSMap, IAS-USA recommends event-driven PrEP as an alternative for cisgender men who have sex with men, following the protocol used in the IPERGAY study: i.e. a double dose (two pills) of TDF/FTC between 24 and two hours in advance of anticipated sex, then, if sex happens, one pill the following day and one the day after – or to be continued daily until two days after the last sex.

The website reported that the group warns against event-driven dosing for women (as vaginal tissue concentrations only reach 10% of rectal concentrations), for all transgender people, and for people at risk through drug injection (for lack of evidence).

Read the full article on AIDSMap.




This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy